The latest advances in targeting PCSK9 therapy in the cardiovascular field
10.20039/j.cnki.1007-3949.2025.10.009
- VernacularTitle:靶向PCSK9治疗在心血管领域的最新进展
- Author:
Lin WANG
1
;
Xuan YANG
;
Jinze FAN
;
Jin'e WU
;
Liuyi HAO
Author Information
1. 长治医学院,山西省长治市 046000;山西医科大学附属运城市中心医院,山西省运城市 044000
- Publication Type:Journal Article
- Keywords:
low density lipoprotein cholesterol;
proprotein convertase subtilisin/kexin type 9;
proprotein conve-rtase subtilisin/kexin type 9 inhibitor;
atherosclerosis;
cardiovascular disease
- From:
Chinese Journal of Arteriosclerosis
2025;33(10):892-900
- CountryChina
- Language:Chinese
-
Abstract:
Proprotein convertase subtilisin/kexin type 9(PCSK9)can modulate low density lipoprotein cholesterol(LDLC)levels,and its dysfunction is closely associated with the progression of atherosclerosis and cardiovascular diseases.Research has shown that PCSK9 inhibitors are highly effective in lowering lipids and have good safety and tolerability.New approaches to targeting PCSK9 inhibition are currently in different stages of clinical development.This review out-lines the primary mechanisms of PCSK9 and its impact on the cardiovascular system,emphasizing the current emerging strategies for targeting PCSK9 in lipid-lowering treatments.
